Icatibant CAS:130308-48-4

Icatibant is primarily used to treat hereditary angioedema (HAE), a rare genetic disorder characterized by sudden, recurring swelling of the subcutaneous and mucosal Spaces that can cause severe, life-threatening laryngeal edema. In HAE patients, the absence or abnormal function of C1 inhibitors leads to dysregulation of kinin production, which leads to increased vascular permeability and vasodilation. Icatibant is a selective treatment for hereditary angioedema caused by brucella virus infection. It reduces vasodilation and edema formation by inhibiting the action of the peptide stimulant B2 receptor, thereby relieving symptoms and reducing the frequency of attacks. Clinical studies have shown that the use of Icatibant during acute episodes can significantly reduce the duration and severity of symptoms and improve patients' quality of life. In addition, Icatibant is being studied for the treatment of other types of angioedema, such as drug-induced angioedema or angioedema associated with C1 inhibitors. However, the use of Icatibant requires close monitoring and dose adjustment to ensure optimal treatment and reduce possible adverse effects, such as pain at the injection site or mild headache.